DnB Asset Management
BCRX icon

DnB Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

DnB Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Sell
14,175
-5,110
-26% -$46.2K ﹤0.01% 1251
2026
Q1 		$184K Buy
+19,285
New +$150K ﹤0.01% 1180

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DnB Asset Management's BCRX Position: Q2 2026 in Review

DnB Asset Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 26% in Q2 2026, selling an estimated $46.2K and leaving 14,175 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #1251.

DnB Asset Management first reported a position in BCRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $184K in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • DnB Asset Management held 14,175 shares of BioCryst Pharmaceuticals worth $142K as of Q2 2026.
  • DnB Asset Management sold 5,110 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $46.2K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #1251 holding.
  • DnB Asset Management first reported a position in BioCryst Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • DnB Asset Management's BioCryst Pharmaceuticals position peaked at $184K in Q1 2026.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.